TimeIsFading
3 days ago
While the specific APIs manufactured by SIGMA Corp in Bolivia are not publicly disclosed, we can make reasonable assumptions about the types of APIs they might produce based on several factors, including their infrastructure, FDA registration, and the typical pharmaceutical market demands in Bolivia and the region. Likely categories of APIs that SIGMA Corp may manufacture include:
1. Generic Drug APIs
Antibiotics: APIs like amoxicillin, azithromycin, or ciprofloxacin to address common bacterial infections.
Analgesics/Antipyretics: APIs such as paracetamol (acetaminophen) or ibuprofen.
Antihistamines: Loratadine or cetirizine for allergy treatments.
2. Chronic Disease APIs
Cardiovascular Drugs: APIs like atorvastatin, enalapril, or losartan for hypertension and cholesterol management.
Antidiabetic Drugs: Metformin or glimepiride for diabetes control.
3. Respiratory and Infectious Disease APIs
Bronchodilators: Salbutamol (albuterol) for asthma.
Antiviral Drugs: Oseltamivir or acyclovir for viral infections.
4. CNS Drugs
APIs such as fluoxetine, sertraline, or alprazolam for mental health conditions.
5. Nutraceutical and Supplement APIs
Vitamins and minerals like ascorbic acid (vitamin C), calcium carbonate, or ferrous sulfate.
6. Over-the-Counter (OTC) APIs
APIs for common OTC products, such as antihistamines, antacids, and topical formulations like hydrocortisone.
Factors Supporting Their Capabilities:
FDA Registration: This suggests the capability to meet international standards, making APIs for export or higher-regulation markets (e.g., the U.S.).
Regional Market Needs: Bolivia's pharmaceutical industry often addresses infectious diseases, respiratory conditions, and chronic illnesses, suggesting a focus on such APIs.
Production Flexibility: SIGMA offers contract manufacturing (maquila services), which indicates the ability to produce diverse APIs tailored to client needs.
If you need highly specific details, contacting SIGMA Corp directly or exploring their product portfolio would provide the most accurate information.
PrivateEquity
3 days ago
Watching these developments at $KRTL is exciting!
KRTL is making a move into the U.S. market with its upcoming line of pharmaceutical products and vitamins, including simple products like ibuprofen, amoxicillin, Vitamin C, and Vitamin D. What makes this venture particularly compelling is the high-profit potential within these categories, driven by their significant markups and relatively low production costs.
This strategy reminds me of a model proven by companies like Costco, which entered the eyeglasses market to disrupt an industry notorious for inflated retail prices. By undercutting competitors with better pricing, Costco made eyewear both affordable for consumers and highly profitable for Costco. I worked for an eyeglass company after college, and the frames cost $1.25 to make, but we were selling them to retail outlets for $100, and at retail the eyeglass frames cost over $200. KRTL sees the same issue with pharmaceuticals that Costco saw with eyeglass frames. Ibuprofen costs pennies, but the retail price is dollars. KRTL has found a nice niche in the pharmaceutical and vitamin industries, which are ripe for cost-effective, high-quality alternatives.
To stand out even further, KRTL is sourcing its Active Pharmaceutical Ingredients (APIs) from Bolivia, a country rich in natural resources and committed to quality. This decision not only ensures cost-effective production but also creates a dependable and sustainable supply chain. By leveraging partnerships in Bolivia, KRTL has non Chinese partners, which is fashionable, and they are aligning with innovative suppliers who support the company’s vision of providing affordable, high-quality products. The officers of KRTL speak Spanish fluently.
This approach offers a win-win: consumers benefit from accessible, high-quality pharmaceuticals and vitamins, while KRTL captures the margin advantage that makes this endeavor so profitable. With Bolivia’s competitive production capabilities and KRTL’s focus on ethical and transparent sourcing, the company is well-positioned to disrupt the U.S. market and achieve substantial growth.
I am eager to turn the clock ahead one year and see all the revenues and the PPS over $1.00, and customers that are household names. So I am posting this information, so I can go back and find it in a year and tell everybody how smart I was for finding this gem. I was here to witness this transformation, step by step.
jobynimble
3 days ago
KRTL Holding Group Inc. Announces Milestone Achievement: FDA Registration of Industria Químico Farmaceutica SIGMA CORP. S.R.L.’s Federal Establishment Identifier
January 22, 2025 09:00 ET
Source: KRTL Holding Group
Lakewood, CO, Jan. 22, 2025 (GLOBE NEWSWIRE) -- KRTL Holding Group Inc. proudly announces the successful registration of Industria Químico Farmaceutica SIGMA CORP. S.R.L. (SIGMA), a premier Bolivian pharmaceutical company, with the United States Food and Drug Administration’s (FDA) Federal Establishment Identifier (FEI). This pivotal milestone highlights the collaboration between KRTL and Sigma in advancing regulatory readiness and enabling access to the highly regulated U.S. market.
Bolivia, renowned for its rich biodiversity and abundant natural resources, offers a wealth of untapped opportunities in the pharmaceutical sector. The partnership between KRTL and SIGMA shines a spotlight on Bolivia’s growing potential as a hub for pharmaceutical innovation and manufacturing. As noted by the U.S. Department of Commerce, “Bolivia presents untapped potential in the development of pharmaceutical manufacturing and export capabilities, offering a promising avenue for partnerships and investments.” This achievement paves the way for Bolivian pharmaceutical products to make their mark on the global stage.
SIGMA, a recognized leader in Bolivia’s pharmaceutical industry, embodies the country’s aspirations to elevate its manufacturing and export capabilities. Through this collaboration, KRTL and SIGMA aim to unlock new possibilities for leveraging Bolivia’s unique natural resources to produce high-quality pharmaceutical products that meet stringent U.S. regulatory standards.
“This registration represents a transformative step in positioning Bolivian-manufactured pharmaceuticals for global opportunities,” stated Cesar Herrara, Chief Executive Officer of KRTL Holding Group Inc. “Bolivia’s wealth of natural resources and innovative potential create a unique foundation for growth. Our partnership with SIGMA reflects KRTL’s commitment to fostering sustainable development and advancing access to healthcare solutions worldwide.”
The FDA registration underscores KRTL’s dedication to regulatory excellence and SIGMA’s commitment to quality manufacturing. Together, the companies are poised to introduce Bolivian ingenuity to international markets, setting a precedent for the future of Bolivia’s pharmaceutical exports and demonstrating the global value of its natural and human resources.
A Vision for the Future
The alliance between KRTL Biotech and SIGMA represents a forward-looking strategy designed to position Bolivia’s pharmaceutical industry as a global player. By blending SIGMA’s advanced manufacturing capabilities with KRTL’s expertise in regulatory compliance and market expansion, this partnership is driving sustainable economic growth and establishing a pathway for Bolivian pharmaceutical exports to reach new markets.
Building on this milestone, KRTL and SIGMA are actively pursuing initiatives to expand production capacity, adopt cutting-edge pharmaceutical technologies, and enter additional high-demand global markets. These efforts reflect a shared commitment to advancing Bolivia’s healthcare infrastructure while contributing to the international pharmaceutical landscape, ensuring sustainable benefits for both local and global communities.
About KRTL Biotech Inc.: KRTL Biotech Inc., a wholly owned subsidiary of KRTL Holding Group Inc., specializes in pharmaceutical registration, regulatory compliance, and FDA services for both international and domestic clients. The company plays a pivotal role in product registration and importation, ensuring seamless integration into the U.S. market. In addition, KRTL Biotech excels in client acquisition, sourcing exclusive APIs, and providing strategic regulatory guidance. Their innovative approach to navigating the complexities of pharmaceutical compliance and market entry positions them as a key driver of success for their partners and clients.
About Industria Químico Farmaceutica SIGMA CORP. S.R.L.
Industria Químico Farmaceutica SIGMA CORP. S.R.L. is a leading pharmaceutical company in Bolivia dedicated to producing high-quality medical products and enhancing healthcare standards. Through strategic collaborations and innovation, Sigma aims to establish Bolivia’s position within the global pharmaceutical industry, ensuring access to essential medications and advancing public health initiatives.
About KRTL Holding Group Inc.
KRTL Holding Group Inc. operates through its wholly owned subsidiaries, KRTL Biotech Inc. and KRTL International Corp., focusing on pharmaceutical innovation and compliance. By fostering strategic partnerships and leveraging synergies across its subsidiaries, KRTL Holding Group enhances shareholder value and maintains a competitive edge in the marketplace.
About Industria Químico Farmaceutica SIGMA CORP. S.R.L.
Industria Químico Farmaceutica SIGMA CORP. S.R.L. is a leading pharmaceutical company in Bolivia dedicated to producing high-quality medical products and enhancing healthcare standards. Through strategic collaborations and innovation, Sigma aims to establish Bolivia’s position within the global pharmaceutical industry, ensuring access to essential medications and advancing public health initiatives.
Additional information on KRTL is available online at www.krtlholding.com and www.krtl-icc.com and www.krtlbiotech.com.
The information contained herein includes forward-looking statements, as defined under the Private Securities Litigation Reform Act of 1995. These statements relate to future events or financial performance and involve risks and uncertainties, including but not limited to market conditions, regulatory approvals, operational challenges, and other factors that could cause actual results to differ materially from those anticipated. KRTL assumes no obligation to publicly update or revise these statements to reflect changes in circumstances or unforeseen events, except as required by law.
https://www.globenewswire.com/news-release/2025/01/22/3013550/0/en/KRTL-Holding-Group-Inc-Announces-Milestone-Achievement-FDA-Registration-of-Industria-Químico-Farmaceutica-SIGMA-CORP-S-R-L-s-Federal-Establishment-Identifier.html
Rattlershehe
1 week ago
As you all know, I've been in the stock for well over two years, and have a small boatload of shares. I believe with everything that has been posted by $KRTL That in the next few weeks, KRTL will make a run to 50 Cent We don't need no cheerleading. We don't need to post things on other boards. We don't need to stand on our head. KRTL is doing the job all by themselves nice and quietly and because of that the big boys are going to start buying very very soon. I believe like I said in the next few weeks. So by all you can right now, because as you can see, nobody is selling
News
Market Data
Register for real-time alerts, custom portfolio, and market movers
Ask ADVFN Intelligence (AI)
Landwehr
2 days ago
threewheeler
5 days ago
ProfitChaser
1 week ago
Kool Aid Man
1 week ago
